Amylyx Pharmaceuticals, Inc. Common Stock

Day range

$28.86 – $30.72

Open

$29.66

Prev close

$29.86

Volume

1.62M

Market cap

$3.84B

Shares out

111.42M

P/E

—

P/S

—

P/B

5.09

P/FCF

—

ROE

-21.6%

ROA

-20.7%

Debt/Equity

0.00

Div yield

0.00%

As of Nov 12, 2026

• Quarterly earningsNov 5, 2026

  On November 5, 2026, Amylyx Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.

• Significant contract awardSep 8, 2026

  On September 8, 2026, Amylyx Pharmaceuticals, Inc. entered into a Manufacturing and Supply Agreement with Bachem Americas, Inc. pursuant to which Bachem will manufacture and supply the Company's long-term supply requirements of avexitide drug substance for commercial use, if approved.

• Public offeringAug 20, 2026

  On August 19, 2026, Amylyx Pharmaceuticals, Inc. entered into an underwriting agreement with Leerink Partners LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and LifeSci Capital LLC, as representatives of the several underwriters named therein, relating to the issuance and sale of an aggregate of 14,090,000 shares of the Company's common stock at a price to the public of $35.50 per share.

• Clinical trial resultsAug 18, 2026

  LUCIDITY met the Food and Drug Administration (the "FDA")-agreed-upon primary endpoint demonstrating a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003). In addition, LUCIDITY met all secondary endpoints demonstrating consistent, highly statistically significant, and clinically meaningful reductions in Level 2 hypoglycemic events by self-monitoring of blood glucose ("SMBG"), Level 2 hypoglycemic events by continuous glucose monitoring ("CGM"), and Level 3 hypoglycemic events.

• Investor presentationAug 18, 2026

  Selected slides from the investor presentation used during the conference call are attached as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference.

Days to cover

10.5

Short interest

12.82M

Avg volume

1.22M

As of Oct 30, 2026 · reported to FINRA twice monthly.

• Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
  positiveThe Motley Fool· Sep 1, 2026
• Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
  positiveGlobeNewswire Inc.· Feb 19, 2026
• Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight
  positiveGlobeNewswire Inc.· Aug 28, 2025
• AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
  negativeGlobeNewswire Inc.· Jul 14, 2025
• AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
  negativeGlobeNewswire Inc.· Jul 7, 2025